Updates
Key figures and quick facts to highlight our work.
In this edition we focus on our valorization efforts of the past months.
![](/oncode/july-2020/updates/18519/oncode_about_icon_copy_15.240_0_1.png)
Meeting Industry
Since 2019, the Oncode Valorization Team had 237 partnering and/or scientific meetings with more than 200 life science companies.
![](/oncode/july-2020/updates/18485/Oncode_Icons_Round_drug_combinations_theme.240_0_1.png)
Therapeutics
We are after new ways to treat cancer. 43% of Oncode’s portfolio is focused on therapeutics.
![](/oncode/july-2020/updates/18512/Oncode_Icons_Round_perturbations_theme.240_0_1.png)
Targets
Oncode Investigators have identified 13 targets that play a role in carcinogenesis.
![](/oncode/july-2020/updates/18501/Oncode_Icons_Round_OnCode_Circle_Icons_26.240_0_1.png)
Clinical Research
Our Clinical Proof of Concept programme supports translational projects. So far, 11 projects are approved. 5 focus on a therapeutic intervention and 6 on a diagnostic approach.
![](/oncode/july-2020/updates/18482/Onc_new_icons_Def_V2_13.240_0_1.png)
Our events
Did you know many Oncode events are open for external participation? This year we organized 3 events with active participation of companies.
![](/oncode/july-2020/updates/18518/Oncode_Icons_Round_tumor_growth_theme.240_0_1.png)
Biomarkers
Biomarker guided therapy makes cancer treatments more effective. 11% of Oncode’s Portfolio is focused on discovery on biomarkers.
![](/oncode/july-2020/updates/18469/corner_grey.128_0_1.png)